Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-02-15
2011-02-15
Desai, Rita J (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S197000, C546S200000, C546S202000, C546S204000, C546S206000, C546S135000, C514S319000, C514S320000, C514S321000, C514S323000, C514S324000, C514S325000
Reexamination Certificate
active
07888510
ABSTRACT:
It was an object of the present invention to provide novel compounds that are suitable in particular as active substances in medicaments, preferably in medicaments for the regulation of neuropeptide Y receptors, particularly preferably of neuropeptide Y5 (NPY5) receptor, for the regulation of food ingestion (food intake), preferably for the prophylaxis and/or treatment of disorders of food ingestion, such as obesity, anorexia, cachexia, bulimia or type II (non insulin dependent) diabetes, for the prophylaxis and/or treatment of disorders of the peripheral nervous system, disorders of the central nervous system, anxiety, depression, cognitive disorders, preferably memory disorders, cardiovascular diseases, pain, epilepsy, arthritis, hypertensive syndrome, inflammatory diseases, immune diseases and other NPY5 mediated disorders in animals and mammals, including man. Said object was achieved by providing 1,4-disubstituted piperidine compounds of general formula (I) wherein the substituents are defined in claim1.
REFERENCES:
patent: 6399631 (2002-06-01), Elliott et al.
patent: 2004/0058920 (2004-03-01), Jover et al.
patent: 2004/0067941 (2004-04-01), Torrens Jover et al.
patent: WO 97/19682 (1997-06-01), None
patent: WO 97/20823 (1997-06-01), None
patent: WO 98/24768 (1998-06-01), None
patent: 98/35957 (1998-08-01), None
patent: WO 98/40356 (1998-09-01), None
patent: WO 99/40091 (1999-08-01), None
patent: WO 00/20376 (2000-04-01), None
patent: 01/07409 (2001-02-01), None
patent: 01/09120 (2001-02-01), None
patent: WO 01/13917 (2001-03-01), None
patent: WO 03/010159 (2003-06-01), None
patent: 03/084939 (2003-10-01), None
In the Pipeline, online, accessed Jun. 16, 2008, “http://pipeline.corante.com/archives/2006/01/24/the—examiner—finally—snaps.php”).
Poindexter G. S. et al. Bioorganic and Medicinal Chemistry Letters 2002, 12, 379-382.
Leslie C. P. Bioorganic and Medicinal Chemistry Letters 2007, 17, 1043-1046.
Finn J. et al Bioorganic and Medicinal Chemistry Letters 2002, 12, 1771-1774.
Jablonowski, J.A. et al. Bioorganic and Medicinal Chemistry Letters 2004, 14, 1239-124.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Kazuhiko Tatemoto, et al., “Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide”, Nature, vol. 296, Apr. 15, 1982, pp. 659-660.
John T. Clark, et al., “Neuropeptide Y and Human Pancreatic Polypeptide Stimulate Feeding Behavior in Rats”, Endocrinology, vol. 115, No. 1, Feb. 20, 1984, pp. 427-429.
A. S. Levine, et al., “Neuropeptide Y: A Potent Inducer of Consummatory Behavior in Rats”, Peptides, vol. 5, 1984, pp. 1025-1029.
B. Glenn Stanley, et al., “Neuropeptide Y: Stimulation of Feeding and Drinking by Injection into the Paraventricular Nucleus”, Life Sciences, vol. 35, No. 26, 1984, pp. 2635-2642.
James F. Flood, et al., “Modulation of memory processing by neuropeptide Y”, Brain Research, vol. 421, 1987, pp. 280-290.
John P. Redrobe, et al., “Multiple receptors for neuropeptide Y in the hippocampus: putative roles in seizures and cognition”, Brain Research, vol. 848, 1999, pp. 153-166.
Markus Heilig, et al., “Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test”, Regulatory Peptides, vol. 41, 1992, pp. 61-69.
Markus Heilig, et al., “Antidepressant drugs increase the concentration of neuropeptide Y (NPY)-like immunoreactivity in the rat brain”, European Journal of Pharmacology, vol. 147, 1988, pp. 465-467.
Martin C. Michel, et al., “Neuropeptide Y: a possible role in hypertension?”, Journal of Hypertension, vol. 13, No. 4, pp. 385-395.
Donald R. Gehlert, “Subtypes of Receptors for Neuropeptide Y: Implications for the Targeting of Therapeutics”, Life Sciences, vol. 55, No. 8, 1994, pp. 551-562.
Philip A. Hipskind, et al., “Section I. Central Nervous System Diseases”, Ann. Rep. Med. Chem., 1996, pp. 1-10.
Lars Grundemar, et al., “Neuropeptide Y effector systems: perspectives for drug development”, Tips Reviews, vol. 15, pp. 153-159.
Yvan Dumont, et al., “BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y2receptor antagonist”, British Journal of Pharmacology, vol. 129, No. 6, 2000, pp. 1075-1088.
Christophe Gerald, et al., “A receptor subtype involve in neuropeptide-Y-induced food intake”, Nature, vol. 382, Jul. 11, 1996, pp. 168-171.
Yinghe Hu, et al., “Identification of a Novel Hypothalamic Neuropeptide Y Receptor Associated with Feeding Behavior”, The Journal of Biological Chemistry, vol. 271, No. 42, Oct. 18, 1996, pp. 26315-26319.
Yvan Dumont, et al., “Characterization of Neuropeptide Y Binding Sites in Rat Brain Membrane Preparations Using [125]Leu31, Pro34]Peptide YY and [125]Peptide YY3-36as Selective Y1and Y2Radioligands1”, The Journal of Pharmacology and experimental Therapeutics, vol. 272, No. 2, 1995, pp. 673-680.
Ants Kask, et al., “Neuropeptide Y Y5receptor antagonist CGP71683A: the effects on food intake and anxiety-related behavior in the rat”, European Journal of Pharmacology, vol. 414, 2001, pp. 215-224.
Andrew V. Turnbull, et al., “Selective Antagonism of the NPY Y5 Receptor Does Not Have a Major Effect on Feeding in Rats”, Diabetes, vol. 51, Aug. 2002, pp. 2441-2449.
B. Glenn Stanley, et al., “Neuropeptide Y injected in the paraventricular hypothalamus: A powerful stimulant of feeding behavior”, Proc. Natl. Acad. Sci. USA, vol. 82, Jun. 1985, pp. 3940-3943.
U.S. Appl. No. 10/566,402, filed Jan. 30, 2006, Torrens Jover, et al.
U.S. Appl. No. 10/566,100, filed Jan. 27, 2006, Torrens Jover, et al.
U.S. Appl. No. 10/566,399, filed Jan. 30, 2006, Torrens Jover, et al.
Angeles Fisas Escasany Maria
Buschmann Helmut-Heinrich
Dordal Zueras Alberto
Mas Prio Josep
Torrens Antoni Jover
Desai Rita J
Laboratorios del Dr. Esteve S.A.
O'Dell David K
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
LandOfFree
2-′4(phenylamino)-piperidin-1-yl!-n-phenyl-acetamine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-′4(phenylamino)-piperidin-1-yl!-n-phenyl-acetamine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-′4(phenylamino)-piperidin-1-yl!-n-phenyl-acetamine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2638440